Recent Pfizer Press Releases

  • 3/24/17 10:18 am EDT

    TRUMENBA Has Been Studied in a Global Clinical Development Program Evaluating the Vaccine in Adolescents and Adults 1

    The Majority of Meningococcal Disease Cases in Europe are Caused by Meningococcal Group B (MenB), with Adolescents and Young Adults at Increased Risk 2

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that TRUMENBA® (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union (EU) for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB).3 The CHMP’smore...
  • 3/22/17 10:30 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2017 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/more...
  • 3/17/17 11:15 am EDT

    In this U.S. Medicare database analysis, Eliquis ® (apixaban) was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. In the analysis, titled Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxabanmore...
  • 3/15/17 9:00 pm EDT
    BEIJING--(BUSINESS WIRE)--Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its oral Janus kinase (JAK) inhibitor, XELJANZ® (tofacitinib citrate), in China for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). It may be used in combination with MTX or other non-biologic disease-more...
  • 3/14/17 5:00 am EDT

    Zavicefta™ Launches Address Urgent Medical Need for New Antibiotics

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that Zavicefta, a novel combination antibiotic for the treatment of patients with certain confirmed or suspected Gram-negative bacterial infections requiring hospitalization, is now available in the U.K. and Germany. Pfizer expects to launch Zavicefta in additional markets outside the U.S. throughout 2017 and 2018. Zavicefta was developed in response to the urgent medical need for new antibiotics for difficult-to-more...
  • 3/6/17 8:30 am EST
    • Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions
    • Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66th Annual Scientific Session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-more...
  • 2/28/17 6:53 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of four tranches of notes: €1,250,000,000 aggregate principal amount of floating rate notes due 2019 €1,000,000,000 aggregate principal amount of 0.000% notes due 2020 €1,000,000,000 aggregate principal amount of 0.250% notes due 2022 €750,000,000 aggregate principal amount of 1.000% notes due 2027 Interest on themore...
  • 2/28/17 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by John Young, Group President, Pfizer Essential Health, at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 37th Annual Healthcare Conference” link inmore...
  • 2/24/17 1:09 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due 2047. This offering is expected to be sold to professional institutional investors in Taiwan, with application to be made to list the notes on the Taipei Exchange. Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial papermore...
  • 2/23/17 4:15 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board. Mr. Blaylock, 57, is the Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006.more...